Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2021
2020
Profitability Metrics
Gross Margin
35.75%
Operating Margin
12.68%
Net Margin
5.44%
Efficiency Metrics
Revenue per Expense Ratio
1.15
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
15.33%
Income Tax Rate
23.73%
EPS
2.7200000000
Balance Sheet Analysis
Current Ratio
0.90
Cash Ratio
0.17
Working Capital
$-3.22B
Debt to Equity
0.53
Debt to Assets
24.22%
Equity Ratio
45.82%
Cash Flow Analysis
Operating Cash Flow Ratio
7.23%
Free Cash Flow Ratio
1.89%
CapEx to Revenue
5.34%
Dividends Paid
$2.90B
Stock Buybacks
No buybacks
Total Shareholder Returns
$2.90B
Cash Position Change
31.29%
Key Takeaways (2024 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
2.77%
Net Income
111.21%
EPS
110.85%
Operating Income
28.81%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
2.76%
Operating Cash Flow
41.61%
Free Cash Flow
74.78%
Balance Sheet Health
Assets
-4.55%
Debt
-2.31%
Book Value per Share
-6.47%
Inventory
3.01%
Shareholder Returns
Dividends per Share
0.00%
Shares Outstanding
-0.16%
Long Term Trends
3Y Revenue/Share
34.85%
5Y Revenue/Share
19.10%
3Y Dividend/Share
0.00%
5Y Dividend/Share
-57.18%